Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology.

Rosén, Harald; Jatzko, G.; Repse, S; Potrč, Stojan; Neudorfer, H; Sandbichler, P.; Zacherl, Johannes; Rabl, Hans; Holzberger, Peter T.; Lisborg, P; Czeijka, M

doi:10.1200/jco.1998.16.8.2733

Cited by 102 publications

(53 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the results from two randomized trials were controversial (25,26) and the effect of i.p. adjuvant therapy has not yet been established (27), this approach seems to be promising (21).…”

Section: Introductionmentioning

confidence: 99%

A Carbohydrate Recognition–Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle

et al. 2006

View full text Add to dashboard Cite

The lymphoid tissue in the omentum, at the so-called milky spots, is known as an initial place for disseminated cancer cells to develop into solid tumors. In the present study, i.p. macrophages significantly took up oligomannose-coated liposomes (OMLs) that were injected into the peritoneal cavity, and then gradually accumulated in the omentum and the other lymphoid tissues within 24 hours of i.p. injection of OMLs. When 5-fluorouracil (5-FU) was encapsulated in the OMLs, >60% of administered 5-FU accumulated in the omentum. Treatment of macrophages at 39°C for 30 minutes led to the release of 5-FU from the macrophages, suggesting that controlled release from macrophages could be achieved by mild hyperthermia. We encased magnetic nanoparticles, which are known to convert electromagnetic energy to heat in the OMLs to achieve in vivo hyperthermia at the site. Using this system in a mouse i.p. metastasis model, we successfully controlled tumor development by coadministration of OML-encased 5-FU and OML-encased magnetic nanoparticles, followed by treatment with an alternating magnetic field. No apparent reduction was seen in tumor growth with the administration of OML-encased magnetic nanoparticles or OML-encased 5-FU alone. Thus, we have established the use of i.p. macrophages as a novel drug delivery system for the control of cancer metastatic to milky spots. (Cancer Res 2006; 66(17): 8740-8)

show abstract

Section: Introductionmentioning

confidence: 99%

A Carbohydrate Recognition–Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle

et al. 2006

View full text Add to dashboard Cite

show abstract

“…In total, these 32 patients received 119 cycles of TACE (median of four cycles). Across both treatment groups, 15 (9.4%) had progressive disease. The median survival time after liver metastasis was 14.7 months (range 7 -37 months; Fig.…”

Section: Resultsmentioning

confidence: 99%

The Effect of Locoregional Transarterial Infusion Chemotherapy on Liver Metastasis after Gastric Cancer Resection

Zhang

Shen

et al. 2012

J Int Med Res

View full text Add to dashboard Cite

“…By contrast, intra-abdominal sepsis without anastomotic leakage (P=0.008) and bleeding (P=0.002) occurred significantly more often in the study group compared with the control group. In a study by Rosen et al (25), significantly higher postoperative complication and mortality rates were also observed in patients receiving intraperitoneal mitomycin bound to activated carbon particles compared with the surgical control group (35 vs. 16.0%; 11 vs. 2.0%, respectively), thus the protocol committee decided to stop further recruitment of patients into that particular study. However, the incidence of surgical complications was only 8.1% in the present study, which was much lower than that in the above-mentioned studies.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer

Xue

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. The optimal adjuvant treatment modality for gastric cancer has not been well defined. The aim of this study was to evaluate the efficacy and feasibility of adjuvant combined systemic and intraperitoneal chemotherapy (ACSIP) in high-risk patients with locally advanced gastric 2 on day 5. Survival rates, the sites of first treatment failure and safety were analyzed. At a median follow-up of 45 months (range 7-101), the 3-year disease-free survival (DFS) and overall survival (OS) rates were 66.1 and 74.2%, respectively. Initial peritoneal and hepatic failures were found in 6 (24.0%) and 3 (12.0%) of the 25 patients with recurrence, respectively. Neutropenia, gastrointestinal side effects and peripheral neuropathy were the most common grade 3-4 toxicities; however, they were all infrequent and manageable. No serious surgical complications or treatment-related mortality was observed. The results of this study indicate that ACSIP is effective and feasible for locally advanced gastric cancer with encouraging survival rates and possibly decreased peritoneal and hepatic recurrences. The benefits of this promising combined adjuvant treatment modality warrant further studies.

show abstract

Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology.

Cited by 102 publications

References 13 publications

A Carbohydrate Recognition–Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle

A Carbohydrate Recognition–Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle

The Effect of Locoregional Transarterial Infusion Chemotherapy on Liver Metastasis after Gastric Cancer Resection

Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer

Contact Info

Product

Resources

About